The major objectives of this research are to determine the chemical mechanism of cyclophosphamide activation and its role in the drug's oncotoxic specificity, and to design and synthesize new cyclophosphamide analogs whose specificity is based upon mechanisms of activation. The primary focus will be on th mechanisms of conversion of 4 hydroxycyclophosphamide to the activated alkylating agent phosphoramide mustard via aldophosphamide and to reversibly deactivated products formed by exchange reaction at the 4 position.
The specific aims of these studies include an understanding of 1) the factors which affect substitution at the 4-position of activated cyclophosphamide derivatives; 2) the role of bifunctional catalysis in the activation of 4-hydroxycyclophosphamide; 3) the significance of the interconversions of activated metabolites with respect to drug activation and transport; and 4) the synthesis of analogs which are designed to reduce bladder toxicity, bypass hepatic activation, or utilize the cyclophosphamide activation pathway to deliver other phosphorylated compounds of therapeutic interest. Nuclear magnetic resonance (NMR) spectrometry, both proton and phosphorus, will be the primary tool for elucidating these mechanisms. Delineation of the activation mechanisms will be of immense importance by increasing our understanding of the factors which affect cyclophosphamide activation, dactivation, and toxicity, and by providing a chemica rationale for the design and synthesis of agents with improved oncotoxic specificity and fewer side effects.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA034619-04
Application #
3172361
Study Section
Medicinal Chemistry Study Section (MCHA)
Project Start
1982-09-01
Project End
1987-05-31
Budget Start
1985-06-01
Budget End
1986-05-31
Support Year
4
Fiscal Year
1985
Total Cost
Indirect Cost
Name
University of Rochester
Department
Type
Schools of Medicine
DUNS #
208469486
City
Rochester
State
NY
Country
United States
Zip Code
14627
Huang, Rong; Oh, Hyunju; Arrendale, Allison et al. (2013) Intracellular targets for a phosphotyrosine peptidomimetic include the mitotic kinesin, MCAK. Biochem Pharmacol 86:597-611
Marian, Christine; Huang, Rong; Borch, Richard F (2011) Design and synthesis of a potential SH2 domain inhibitor bearing a stereodiversified 1,4-cis-enediol scaffold. Tetrahedron 67:10216-10221
Clark, Michelle K; Scott, Sarah A; Wojtkowiak, Jonathan et al. (2007) Synthesis, biochemical, and cellular evaluation of farnesyl monophosphate prodrugs as farnesyltransferase inhibitors. J Med Chem 50:3274-82
Choi, Jun Young; Borch, Richard F (2007) Highly efficient synthesis of enantiomerically enriched 2-hydroxymethylaziridines by enzymatic desymmetrization. Org Lett 9:215-8
Wu, Weidong; Sigmond, Jennifer; Peters, Godefridus J et al. (2007) Synthesis and biological activity of a gemcitabine phosphoramidate prodrug. J Med Chem 50:3743-6
Boutselis, Irene G; Yu, Xiao; Zhang, Zhong-Yin et al. (2007) Synthesis and cell-based activity of a potent and selective protein tyrosine phosphatase 1B inhibitor prodrug. J Med Chem 50:856-64
Garrido-Hernandez, Hugo; Moon, Kyung D; Geahlen, Robert L et al. (2006) Design and synthesis of phosphotyrosine peptidomimetic prodrugs. J Med Chem 49:3368-76
Wu, Weidong; Borch, Richard F (2006) Synthesis and biological activity of N-2,3-dihydroxypropyl-N-4-chlorobutyl nucleoside phosphoramidate prodrugs. Mol Pharm 3:451-6
Wu, Weidong; Freel Meyers, Caren L; Borch, Richard F (2004) A novel method for the preparation of nucleoside triphosphates from activated nucleoside phosphoramidates. Org Lett 6:2257-60
Tobias, Sandra C; Borch, Richard F (2004) Synthesis and biological evaluation of a cytarabine phosphoramidate prodrug. Mol Pharm 1:112-6

Showing the most recent 10 out of 32 publications